Actinium presents first-in-human data for ATNM-400 at EANM 2026; shares jump ~21%

Actinium Pharmaceuticals presented first-in-human data for ATNM-400, an Actinium-225 radiotherapy for metastatic castration-resistant prostate cancer targeting HER3, at EANM 2026 in Vienna. Shares jumped about 21% on the news.

Detected & updated continuously · Source: Nebula